Generic Medicine Info
Indications and Dosage
Primary herpes simplex keratoconjunctivitis, Recurrent herpes simplex virus epithelial keratitis
Adult: As 1% soln: Instill 1 drop into affected eye 2 hrly. Max: 9 drops daily, until complete re-epithelialisation. Reduce to 1 drop 4 hrly (Min 5 drops daily) for 7 days. Treatment should not exceed 21 days.
Child: ≥6 yr Same as adult dose.
Special Precautions
Childn. Pregnancy and lactation.
Adverse Reactions
Mild conjunctival or corneal irritation/burning/stinging, palpebral and stromal oedema, superficial punctate and epithelial keratopathy, hyperaemia, increased intraocular pressure.
Mechanism of Action: Trifluridine is a fluorinated pyrimidine nucleoside that is active against HSV, vaccinia virus, CMV, and some adenovirus. It interferes w/ viral replication by inhibiting thymidylate synthetase and incorporating into viral DNA in place of thymidine.
Onset: W/in 2-7 days.
Absorption: Absorbed through the cornea w/ increased penetration in the presence of epithelial defect or w/ stromal/uveal inflammation.
Excretion: Elimination half-life: 12 min.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Trifluridine, CID=6256, (accessed on Jan. 23, 2020)

Store between 2-8˚C.
MIMS Class
Eye Anti-Infectives & Antiseptics
ATC Classification
S01AD02 - trifluridine ; Belongs to the class of antiinfectives, antivirals. Used in the treatment of eye infections.
Anon. Trifluridine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 08/07/2016.

Buckingham R (ed). Trifluridine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 08/07/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Trifluridine (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 08/07/2016.

Trifluridine Solution (Falcon Pharmaceuticals, Ltd.). DailyMed. Source: U.S. National Library of Medicine. Accessed 08/07/2016.

Disclaimer: This information is independently developed by MIMS based on Trifluridine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in